# Oral Vinorelbine as Induction Chemotherapy Followed Concomitant Chemoradiotherapy

> **NCT01839032** · PHASE2 · COMPLETED · sponsor: **Pierre Fabre Medicament** · enrollment: 70 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Vinorelbine cisplatin radiotherapy

## Key facts

- **NCT ID:** NCT01839032
- **Lead sponsor:** Pierre Fabre Medicament
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2013-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01839032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01839032, "Oral Vinorelbine as Induction Chemotherapy Followed Concomitant Chemoradiotherapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01839032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*